| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2019 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FEMASYS INC | 13 | Q2 2024 | 0.5% |
| REGENERON PHARMACEUTICALS | 12 | Q2 2024 | 13.8% |
| XENON PHARMACEUTICALS INC | 11 | Q2 2024 | 4.7% |
| ARGENX SE | 10 | Q2 2024 | 12.8% |
| AVADEL PHARMACEUTICALS PLC | 10 | Q2 2024 | 7.0% |
| LILLY ELI & CO | 9 | Q2 2023 | 9.5% |
| STEVANATO GROUP S P A | 8 | Q2 2024 | 5.8% |
| X4 PHARMACEUTICALS INC | 8 | Q3 2023 | 3.0% |
| TEVA PHARMACEUTICAL INDS LTD | 7 | Q2 2024 | 10.8% |
| AXSOME THERAPEUTICS INC | 7 | Q2 2024 | 6.2% |
View Tri Locum Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-27 |
| 13F-HR | 2023-02-14 |
View Tri Locum Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.